



Citi Pharma Limited

January 30, 2025

The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi

Subject: **Board Meeting Other Than Financial Results**

Dear Sir,

This is to inform you that a meeting of the Board of Directors of the Company will be held on 2025-02-06 at 12:30pm at Lahore to consider the following agenda items:

Item No	Agenda Items
1.	Confirmation of the minutes of Board of Directors meeting held on October 29, 2024
2.	To consider and approve of biological section / plant including separate facilities for different types of Insulin (Regular Insulin, Glargine, Lispro, Aspart, Detemir, Degludec), GLP-1 (Semaglutide and Bio-similar)
3.	To consider and approval of Carbapenems (<i>Imipenem, Meropenem, Doripenem, Ertapenem</i>) section/ plant
4.	To consider and approval of Antibiotic plant for formulation section.
5.	To consider the formation of and approval for establishment of Citi REIT Management Company as a wholly owned subsidiary of Citi Pharma Limited and to allow formation of an approval of fund raising for real estate projects.
6.	To consider and approval to entering into discussions (Stage 3) pertaining to the formation of a Joint Venture with international partners for the development of a hospital as published in the Company's IPO prospectus.
7.	Any other matter with the permission of the Chair.

The Company has declared the "Closed Period" from 2025-01-30 to 2025-02-06 as required under Clause 5.6.1(d) of PSX Regulations. Accordingly, no Director, CEO or Executive shall, directly / indirectly, deal in the shares of the Company in any manner during the Closed Period.

Please inform the TRE Certificate Holders of the Exchange accordingly.

Yours Sincerely,



588 - Q, Johar Town, Lahore - Pakistan



3KM, Heed Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk